Image Credit: fx79/123rf.com
Tim Friede, a man who has been intentionally bitten by venomous snakes approximately 200 times, is at the forefront of a potential breakthrough in snakebite treatment. His unique approach aims to create a universal antivenom that could save lives in regions heavily affected by snakebites.
Each year, snakebites result in tens of thousands of fatalities and countless injuries, particularly in tropical and low-income areas. The consequences of snake venom can include paralysis, loss of limbs, and even death. Traditional antivenoms, which are derived from horse antibodies, are often costly and tailored to specific snake species, making them less effective in diverse environments.
Biotech company Centivax, led by CEO Jacob Glanville, has identified Friede’s immune system as a promising source of antibodies that could help combat snake venom. Researchers discovered a potent antibody in Friede’s blood that effectively neutralizes neurotoxins responsible for paralysis. In tests conducted on mice, this antibody demonstrated full protection against five different snake species, including the highly dangerous black mamba.
The research team expanded their findings by adding two additional components—a second antibody from Friede and a molecule known as varespladib. This three-part combination successfully protected mice from the effects of 13 different snake species and provided partial protection against six more, showcasing a significant advancement in antivenom development.
While this represents a significant step forward, experts stress the importance of human trials to ensure the treatment’s efficacy against the various toxins present in snake venom. Currently, viper species, which account for nearly half of the world’s venomous snakes, are not covered by this new cocktail, but Centivax plans to broaden its scope.
The global antivenom market is estimated to be worth around $600 million, making the development of a universal solution not only a humanitarian milestone but also a potential commercial success. As the research progresses, Friede has transitioned into the role of director of herpetology at Centivax, where he continues to contribute to this groundbreaking work.
Check out the original article here: Source link
